Transforming patients’ lives by leading innovation in nuclear medicine. At Advanced Accelerator Applications, a Novartis Company, we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.
An innovative medicines company focused on the development of products for targeted radioligand therapy, and precision radioligand imaging as well as molecular imaging products, that currently markets 2 targeted radioligand therapy in oncology and several precision imaging products mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.
We also have an active research and development pipeline of investigational drugs using radiolabelled targeting molecules in multiple cancer types.
Our business is structured to improve efficiencies and drive innovation. We are able to generate or reliably source radioisotopes (e.g. F-18, Lu-177), and conduct much of our own research and development, in addition to having in-house commercial manufacturing and marketing capabilities. We operate at 18 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands.
Advanced Accelerator Applications, a Novartis Company, is a pioneer in the field of nuclear medicine theranostics, with an expanding pipeline of complementary precision imaging radioligands and targeted radioligand therapies for oncology indications. Theranostics is a disease management strategy involving the integration of nuclear medicine diagnostic imaging and therapy. Nuclear Medicine is a medical specialty that uses targeted radiopharmaceuticals to image and treat diseases.
In the context of nuclear medicine, theranostics refers to the use of targeting molecules labeled either with diagnostic imaging radioisotopes, e.g., positron or gamma emitters, such as fluorine 18 (F-18) or gallium 68 (Ga-68), or with radioisotopes used for therapy, e.g., alpha or beta emitters such as radium 223 (Ra-223), lutetium 177 (Lu-177) or actinium 225 (Ac-225) for radioligand imaging and targeted radioligand therapy of a particular disease.
Using similar molecular targeting compounds in this manner also enables a more complete approach to disease management, because diagnostic imaging can then serve several simultaneous functions:
- assessing disease,
- selection for therapy
For patients, a theranostic approach may lead to more effective care, by selecting patients who would benefit the most from certain therapeutic interventions, while reducing or eliminating unnecessary treatment. This makes the theranostic approach both efficient and patient-centric.
For physicians, theranostics may enhance their ability to diagnose and stage disease, select optimal therapies, and monitor treatment response and disease progression, improving prognostic capability for better health outcomes.
For payors, theranostic approaches may reduce costs associated with suboptimal diagnostics and treatments and shorten the time needed to properly assess and treat patients with effective individualized treatment plans.